Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.

After significant effort over the last 30 years, antibody-drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date, with additional ADCs in late stages of development. Here, we introduce dolaflexin, a novel ADC technology that overcomes key limitations of the most common ADC platforms with two key features: a higher drug-to-antibody ratio and a novel auristatin with a controlled bystander effect. The novel, cell permeable payload, auristatin F-hydroxypropylamide, undergoes metabolic conversion to the highly potent, but less cell permeable auristatin F to balance the bystander effect through drug trapping within target cells. We conducted studies in mice, rats, and cynomolgus monkeys to complement in vitro characterization and contrasted the performance of dolaflexin with regard to antitumor activity, pharmacokinetic properties, and safety in comparison with the ADC platform utilized in the approved ADC ado-trastuzumab emtansine (T-DM1). A HER2-targeted dolaflexin ADC was shown to have a much lower threshold of antigen expression for potent cell killing in vitro, was effective in vivo in tumors with low HER2 expression, and induced tumor regressions in a xenograft model that is resistant to T-DM1.

Evaluation of electrospray ionization mass spectrometry as a tool for characterization of small soluble protein aggregates.

Protein aggregation continues to attract significant interest in many areas of biology and medicine not only due to its pivotal role in the etiology of conformational diseases (such as Parkinson's and Alzheimer's) but also due to its importance in the biopharmaceutical sector, where aggregation of protein therapeutics exerts a deleterious effect on their efficacy and safety. Despite the tremendous success of electrospray ionization mass spectrometry (ESI MS) in a large number of studies of noncovalent protein interactions, application of this technique to study aggregation processes has been very limited so far, and lower resolution techniques, such as size exclusion chromatography (SEC) and analytical ultracentrifugation, remain the default tools in characterizing small soluble protein aggregates. In this work we used heat-stressed human antithrombin III (AT), a 58 kDa glycoprotein, to compare SEC and ESI MS as a means to probe composition of the complex mixture of soluble oligomeric species generated by heat-induced aggregation. SEC allows several oligomeric species to be observed and collected, followed by their identification with ESI MS. The same oligomeric species can be also directly observed in the ESI MS of the unfractionated sample of the heat-stressed AT. The abundance distribution of these small soluble aggregates in ESI MS and SEC cannot be compared directly, since the ESI signal is linked to the molar concentration of the analyte in solution, whereas the UV absorption detection in SEC reports weight concentration. However, once the appropriate corrections are made, the abundance of the small aggregates derived from ESI MS becomes remarkably close to that calculated based on SEC data, suggesting that ESI MS may be directly applied for semiquantitative characterization of soluble protein aggregates.